Mangosteen-derived Mangostin as a Topical Prophylaxis Against Catheter-related Infections: A Multicenter, Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250326007

Enrollment

Registered

2025-03-26

Start date

2024-07-05

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AKI, ESKD patients with new access of non tunneled hemodialysis catheter mangostin, non-tunneled hemodialysis catheter, exit site infection, catheter related blood stream infection

Interventions

Mangostin ointment were applied identically to the catheter exit site immediately after insertion of the non-tunneled hemodialysis catheter and every session of hemodialysis. All patients were monito

Active Comparator Drug,Placebo Comparator Drug

Mangostin ointment,Placebo

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.AKI or ESKD 2.Placement of new non-tunneled hemodialysis catheters

Exclusion criteria

Exclusion criteria: 1.Known allergy to mangosteen 2. Undergoing CRRT 3.Colonization with drug-resistant organisms 4.Currently receiving antibiotic treatment

Design outcomes

Primary

Measure	Time frame
composite of exit site infection and Catheter related blood stream infection Removal of non-tunneled hemodialysis catheter rate of infection	—

Secondary

Measure	Time frame
Catheter-related blood stream infection removal of non tunneled hemodialysis catheter infection rate	—

Countries

Thailand

Contacts

Public ContactSutthikarn Ruammek

Phramongkutklao hospital

sutthikarn.ruam@gmail.com0847136610

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026